Point-of-Care Malaria MDx Project Funded by EU and Using QuantuMDx Technology is Ahead of Schedule
Nanomal, a European Union-funded public-private consortium developing a handheld device for rapid, point-of-care molecular diagnosis of malaria and drug resistance, said this week that the instrument is a year ahead of schedule and will be ready for field testing later this year.
QuantumDx Leading $4.5M UK-Supported Project to Develop Rapid Molecular Tumor Profiling Device
QuantumDx is heading a UK-based public-private partnership to develop a chip-based molecular profiling tool for diagnosing and staging cancer, and potentially guiding oncology treatments.
Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …
Mar 24, 2009